Larotrectinib
Larotrectinib, a selective inhibitor of tropomyosin receptor kinase, has been effective in pediatric tumors with Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion mutations in children as young as 1-month-old.
Offenbacher et al. shared the case of a 9-month-old boy who presented with a 4-month history of regression of his milestones and severe constipation who was found to have a large spinal pilocytic astrocytoma with multiple intracranial periventricular lesions 1)
1)
Offenbacher R, Kobets A, Dalvi N, Hsu K, Chin S, Snuderl M, Levy A, Martin A. A nine-month-old boy with regression of milestones and severe constipation: an unusual case of a large spinal NTRK1 fusion pilocytic astrocytoma. Childs Nerv Syst. 2022 Sep 15. doi: 10.1007/s00381-022-05662-w. Epub ahead of print. PMID: 36107222.